SCHEMBL12756514

SCHEMBL12756514

O=C(Nc1csc(-c2ccc(Cl)cc2)c1C(=O)O)c1ccco1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ KMT2A Q03164 4/20 0.52
▸ TP53 P04637 3/20 0.52
▸ TSHR P16473 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ KCNMA1 Q12791 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ LMNA P02545 3/20 0.48
▸ MAPT P10636 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12756510 0.88 RAB9A (0.53) NPC1RAB9AKMT2ATP53TSHR
SCHEMBL12756545 0.82 ANO1 (0.49) NPC1RAB9AKMT2ATP53MEN1
SCHEMBL15480667 0.81 MAPT (0.54) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL1490509 0.81 KMT2A (0.55) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL15480567 0.81 KMT2A (0.47) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL12756723 0.79 MEN1 (0.59) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL12756722 0.79 NTRK1 (0.49) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL1490461 0.79 NPC1 (0.57) NPC1RAB9AKMT2ATP53TSHR
SCHEMBL1490373 0.79 KMT2A (0.52) NPC1RAB9AKMT2ATP53SMN1; SMN2
SCHEMBL1951227 0.79 ALDH1A1 (0.82) NPC1RAB9AKMT2ATP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2014-02-20 — — US disclosed
WO-2011034962-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-03-24 — — WO disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051711-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885KMT2A 4706/4885
US-20110065724-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885KMT2A 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback